Can-Fite BioPharma annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Stock-Based Compensation Growth & History (CANF)
Can-Fite BioPharma's stock-based compensation was $340,000 for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $340,000 | −$22,000 | −6.08% |
| 2024 | 2024-12-31 | $362,000 | $101,000 | +38.70% |
| 2023 | 2023-12-31 | $261,000 | −$2,000 | −0.76% |
| 2022 | 2022-12-31 | $263,000 | −$203,000 | −43.56% |
| 2021 | 2021-12-31 | $466,000 | $111,000 | +31.27% |
| 2020 | 2020-12-31 | $355,000 | −$30,000 | −7.79% |
| 2019 | 2019-12-31 | $385,000 | −$150,000 | −28.04% |
| 2018 | 2018-12-31 | $535,000 | $343,000 | +178.65% |
| 2017 | 2017-12-31 | $192,000 | −$130,000 | −40.37% |
| 2016 | 2016-12-31 | $322,000 | — | — |
Can-Fite BioPharma stock-based compensation trends
Over the last five fiscal years, Can-Fite BioPharma's stock-based compensation decreased from $355,000 to $340,000, a change of −$15,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma source filings ↗